loader2
Login Open ICICI 3-in-1 Account

OneSource Specialty Pharma Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
OneSource Specialty Pharma Ltd. 12 Nov 2025 12:03 PM

Q2FY26 Quarterly Result Announced for OneSource Specialty Pharma Ltd.

Pharmaceuticals company OneSource Specialty Pharma announced Q2FY26 results

  • Revenues at Rs 3,758 million, up 12% YoY.
  • EBITDA grew 37% YoY to Rs 1,065 million.
  • EBITDA margin of 28%, an expansion of ~506 bps YoY.
  • Adjusted PAT stood at Rs 449 million with adjusted EPS of Rs 3.9.

Neeraj Sharma, CEO & MD, OneSource Specialty Pharma, said: “Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity addition is being accelerated to support upcoming customer launches. We are excited about recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India and accordingly are raising our FY28 revenue outlook to USD 500 million .”

Result PDF

Pharmaceuticals company OneSource Specialty Pharma announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue: for Q4FY25 Rs 4,260 million, up 22% YoY.
  • EBITDA grew 79% YoY 1,825 million during Q4FY25.
  • Q4FY25 EBITDA margin of 43%, an expansion of 1,362 basis points YoY
  • Q4FY25 PAT stood at Rs 992 million with adjusted EPS of Rs 12.2.

FY25 Financial Highlights:

  • Revenue: for FY25 Rs 14,449 million, up 30% YoY.
  • FY25 EBITDA grew 104% YoY 4,665 million.
  • FY25 EBITDA margin of 32%, a YoY expansion of 1,165 basis points.
  • FY25 PAT Rs 9361 million adjusted for one-time exceptional items.
  • 39 new RFPs/ licensing deals won with ~50% coming from existing customers.

Neeraj Sharma, CEO & MD, OneSource Specialty Pharma,said: "We're delighted to announce 30% revenue increase, driven by all-round robust growth. EBITDA grew significantly due to product mix in favour of Drug Device Combinations (DDCs) and Biologics, and higher operational efficiencies. Our business has been driven by strong customer acquisition and new MSAs. With the successful on-going integration of the acquired entities, we're achieving cross-selling opportunities, and cost synergies, creating greater value for customers and shareholders."

Result PDF

Pharmaceuticals company OneSource Specialty Pharma announced Q3FY25 results

  • Revenues of Rs 3,926 million grew 18% QoQ.
  • EBITDA grew 85% QoQ to Rs 1,432 million.
  • EBITDA margin of 36.5% grew by 1,334 basis points QoQ.
  • Q3FY25 normalized PAT was Rs 898 million, resulting in an EPS of Rs 7.8 for the quarter.
  • Reported PAT was impacted by one-time OneSource setup and transaction costs.

Neeraj Sharma, CEO, OneSource Specialty Pharma, said: “We're off to a promising start as an independent platform. Our strong Q3 results and impressive new business wins across various modalities demonstrate we're on the path to continued growth and profitability while achieving the targeted FY25 outcomes. We're committed to providing significant value and establishing ourselves as the leading Indian CDMO on a global stage.”

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app